Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
Conditions: Anatomic Stage IV Breast Cancer AJCC v8; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Malignant Solid Neoplasm; Metastatic Triple-Negative Breast Carcinoma; Metastatic Urothelial Carcinoma; Prognostic Stage IV Breast Cancer AJCC v8; Stage IV Lu ng Cancer AJCC v8; Stage IVA Lung Cancer AJCC v8; Stage IVB Lung Cancer AJCC v8 Interventions: Drug: Atezolizumab; Drug: Cyclophosphamide; Drug: Fludarabine; Biological: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells; Biological: PD1 Inhibitor Sponsors: Fred Hutchinson Cancer Research Center; SignalOne Bio, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Research